Search results
Showing 6946 to 6960 of 8213 results
Baricitinib for treating active autoantibody-positive systemic lupus erythematosus [ID3997]
Discontinued Reference number: GID-TA10892
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
In development Reference number: GID-TA10900 Expected publication date: TBC
In development Reference number: GID-TA10905 Expected publication date: TBC
Tanezumab for treating pain caused by bone metastases [ID3784]
Discontinued Reference number: GID-TA10922
Nivolumab for neoadjuvant and adjuvant treatment of localised renal cell carcinoma [ID4047]
Discontinued Reference number: GID-TA10927
Discontinued Reference number: GID-TA10934
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]
In development Reference number: GID-TA10935 Expected publication date: TBC
Durvalumab with chemoradiation for untreated locally advanced cervical cancer [ID5081]
Discontinued Reference number: GID-TA10963
Bempegaldesleukin with nivolumab for untreated unresectable or metastatic melanoma
Discontinued Reference number: GID-TA10970
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]
In development Reference number: GID-TA11010 Expected publication date: TBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]
In development Reference number: GID-TA11022 Expected publication date: TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]
In development Reference number: GID-TA11070 Expected publication date: TBC
Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]
Discontinued Reference number: GID-TA10633
Savolitinib for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID1638]
Discontinued Reference number: GID-TA10634
Discontinued Reference number: GID-TA10635